The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Race and the Response to Adrenergic Blockade with Carvedilol in Patients with Chronic Heart Failure
Open accessAbstract
BACKGROUND: The benefits of angiotensin-converting-enzyme inhibitors and beta-blockers may be smaller in black patients than in patients of other races, but it is unknown whether race influences the response to carvedilol in patients with chronic heart failure. METHODS: In the U.S. Carvedilol Heart Failure Trials Program, 217 black and 877 nonblack patients (in New York Heart Association class II, III, or IV and with a left ventricular ejection fraction of no more than 0.35) were randomly assigned to receive placebo or carvedilol (at doses of 6.25 to 50 mg twice daily) for up to 15 months. The effects of carvedilol on ejection fraction, clinical status, and major clinical events were retrospectively compared between black and nonblack patients. RESULTS: As compared with placebo, carvedilol lowered the risk of death from any cause or hospitalization for any reason by 48 percent in black patients and by 30 percent in nonblack patients. Carvedilol reduced the risk of worsening heart failure (heart failure leading to death, hospitalization, or a sustained increase in medication) by 54 percent in black patients and by 51 percent in nonblack patients. The ratios of the relative risks associated with carvedilol for these two outcome variables in black as compared with nonblack patients were 0.74 (95 percent confidence interval, 0.42 to 1.34) and 0.94 (95 percent confidence interval, 0.43 to 2.05), respectively. Carvedilol also improved functional class, ejection fraction, and the patients' and physicians' global assessments in both the black patients and the nonblack patients. For all these measures of outcome and clinical status, carvedilol was superior to placebo within each racial cohort (P<0.05 in all analyses), and there was no significant interaction between race and treatment (P> 0.05 in all analyses). CONCLUSIONS: The benefit of carvedilol was apparent and of similar magnitude in both black and nonblack patients with heart failure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart Failure
Packer, M., Bristow, M. R., Cohn, J. N., Colucci, W. S., Fowler, M. B., Gilbert, E. M., & Shusterman, N. H. (1996) · New England Journal of Medicine · doi:10.1056/nejm199605233342101 · Cited by 4,649
Self-citationBristow, M. R., Gilbert, E. M., Abraham, W. T., Adams, K. F., Fowler, M. B., Hershberger, R. E., Kubo, S. H., Narahara, K. A., Ingersoll, H., Krueger, S., et al. (1996) · Circulation · doi:10.1161/01.cir.94.11.2807 · Cited by 1,303
Self-citationMaterson, B. J., Reda, D. J., Cushman, W. C., Massie, B. M., Freis, E. D., Kochar, M. S., Hamburger, R. J., Fye, C., Lakshman, R., Gottdiener, J., et al. (1993) · New England Journal of Medicine · doi:10.1056/nejm199304013281303 · Cited by 1,199
Carvedilol Inhibits Clinical Progression in Patients With Mild Symptoms of Heart Failure
Colucci, W. S., Packer, M., Bristow, M. R., Gilbert, E. M., Cohn, J. N., Fowler, M. B., Krueger, S. K., Hershberger, R., Uretsky, B. F., Bowers, J. A., et al. (1996) · Circulation · doi:10.1161/01.cir.94.11.2800 · Cited by 635
Self-citationPacker, M., Colucci, W. S., Sackner-Bernstein, J. D., Liang, C.-S., Goldscher, D. A., Freeman, I., Kukin, M. L., Kinhal, V., Udelson, J. E., Klapholz, M., et al. (1996) · Circulation · doi:10.1161/01.cir.94.11.2793 · Cited by 613
Self-citationExner, D. V., Dries, D. L., Domanski, M. J., & Cohn, J. N. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441802 · Cited by 567
Self-citationCarson, P., Ziesche, S., Johnson, G., & Cohn, J. N. (1999) · Journal of Cardiac Failure · doi:10.1016/s1071-9164(99)90001-5 · Cited by 533
Self-citationRacial Differences in the Outcome of Left Ventricular Dysfunction
Dries, D. L., Exner, D. V., Gersh, B. J., Cooper, H. A., Carson, P. E., & Domanski, M. J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199902253400804 · Cited by 368
Ghali, J. K. (1990) · Archives of Internal Medicine · doi:10.1001/archinte.150.4.769 · Cited by 311
Giugliano, D., Acampora, R., Marfella, R., De Rosa, N., Ziccardi, P., Ragone, R., De Angelis, L., & D'Onofrio, F. (1997) · Annals of Internal Medicine · doi:10.7326/0003-4819-126-12-199706150-00004 · Cited by 302
Cited by
ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult
Hunt, S. A. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.08.022 · Cited by 4,154
2005 WRITING COMMITTEE MEMBERS, Hunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., Ganiats, T. G., Jessup, M., Konstam, M. A., Mancini, D. M., et al. (2009) · Circulation · doi:10.1161/circulationaha.109.192065 · Cited by 3,720
Self-citationWRITING COMMITTEE MEMBERS, Hunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., Ganiats, T. G., Jessup, M., Konstam, M. A., Mancini, D. M., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.167586 · Cited by 2,251
Self-citation(2006) · Project Muse (Johns Hopkins University) · Cited by 2,029
Combination of Isosorbide Dinitrate and Hydralazine in Blacks with Heart Failure
Taylor, A. L., Ziesche, S., Yancy, C., Carson, P., D'Agostino, R., Ferdinand, K., Taylor, M., Adams, K., Sabolinski, M., Worcel, M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042934 · Cited by 1,773
Self-citation
Metadata
- Authors
- Yancy, C. W., Fowler, M. B., Colucci, W. S., Gilbert, E. M., Bristow, M. R., Cohn, J. N., Lukas, M. A., Young, S. T., & Packer, M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2001-05-03
- Volume
- 344
- Issue
- 18
- Pages
- 1358-1365
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2336619635
- Cited by
- 288
- References
- 30
- FWCI
- 28.80
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Race and the Response to Adrenergic Blockade with Carvedilol in Patients with Chronic Heart Failure. https://app.cochat.ai/papers/10.1056/nejm200105033441803
- The paper
- Yancy, C. W., Fowler, M. B., Colucci, W. S., Gilbert, E. M., Bristow, M. R., Cohn, J. N., Lukas, M. A., Young, S. T., & Packer, M. (2001). Race and the Response to Adrenergic Blockade with Carvedilol in Patients with Chronic Heart Failure. New England Journal of Medicine. https://doi.org/10.1056/nejm200105033441803
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.